Tools chosen: kalshi_direct claude_news congress_bills kalshi_related polymarket_related gdelt_news

Sub-questions (Fermi decomposition)

Planner reasoning

This is a policy-action question resolving Yes if Trump takes an action eliminating the cost of at least one IVF cycle before Jan 2029. The key drivers are Trump's stated commitments, any executive orders or legislative movement on IVF, and feasibility given federal budget/legal constraints. Market price is the primary anchor.

# Current state The resolution criterion requires Trump to take an action that *eliminates the cost* of at least one IVF cycle before Jan 20, 2029. As of mid-2026, all administration actions have been incremental cost-reduction measures (drug discounts, voluntary employer benefit frameworks) — none eliminate IVF costs. The White House has explicitly signaled it will not mandate insurance coverage. # Timeline of key events - **2025-02-18** — Trump signs EO directing policy recommendations on IVF access/cost reduction within 90 days. [confirmed, resolve.org / segalco.com] - **2025-05-19** — 90-day EO deadline passes; no recommendations released, no timeline given. [confirmed, NBCNews] - **2025-05-19** — HR 3480 (Health Coverage for IVF Act) introduced; referred to committee. [confirmed, congress.gov] - **2025-10-16** — Admin announces two-part IVF initiative: drug discounts (EMD Serono, 84% off list price on select meds) + employer standalone fertility benefit pathway. [confirmed, ASRM] - **2026-02-05** — TrumpRx.gov launched; includes reduced fertility medication pricing. [confirmed, Prelude Fertility] - **2026-05-11** — Proposed rule (Labor/HHS/Treasury) for optional employer "limited excepted benefit" up to $2,150/year for fertility expenses — voluntary, not mandatory. [confirmed, PBS NewsHour] - **2026-05-12** — Trump publicly struggles to articulate IVF plan at press event. [reported, Atlanta Black Star] - **2026-06-10** — Trump admin moves to protect frozen embryos from destruction, complicating IVF practice. [reported, Daily Signal] --- # Event Will Trump take action eliminating the cost of at least one IVF cycle before Jan 20, 2029? # Outcomes to forecast - **Yes** — Trump takes action eliminating cost of ≥1 IVF cycle before Jan 20, 2029 - **No** — No such action taken # Kalshi market anchor **Current YES price: 14%** | 7-day change: −2% | 30-day change: −1% | Range over 62 days: 12–17% | Avg daily volume: 38 contracts. Trend is mildly downward and stable at low probability. # Sub-question answers 1. **Has Trump signed any EO mandating free/covered IVF?** — No. The Feb 2025 EO only directed policy recommendations; it imposes no coverage mandate. [resolve.org, segalco.com] 2. **What did the Feb 2025 EO actually require, and has it produced cost elimination?** — The EO directed the Deputy Domestic Policy Advisor to produce recommendations within 90 days. That deadline passed with no output. Subsequent actions (drug discount deal, voluntary employer benefit) do not eliminate IVF costs. [NBCNews, ASRM, KFF] 3. **Is there federal legislation to fund free IVF?** — No enacted legislation. Five bills introduced (HR 3480, S 2035, S 1231, HR 6797, HR 2557), all Democratic-sponsored or bipartisan for military only; all stuck in committee. [congress.gov] 4. **What legal/budgetary obstacles exist?** — No existing federal law mandates IVF coverage. White House has explicitly rejected an insurance mandate. Congressional action required for a funding mechanism; Republican-controlled Congress has not advanced any IVF coverage bill. Executive authority alone is insufficient. [segalco.com, KFF] 5. **Current Kalshi price?** — 14% YES, trending slightly down. [kalshi_direct] # Key facts (high-confidence, factual) 1. [ASRM] Employer "limited excepted benefit" capped at $2,150 — a single IVF cycle costs ~$12,000–$25,000+; cap is far below full cost. 2. [KFF] No federal law mandates infertility treatment coverage; legislation is necessary for a true mandate. 3. [Washington Post / reproductivefreedomforall.org] White House explicitly does not plan to require insurers to cover IVF. 4. [NBCNews] EO's 90-day recommendation deadline missed with no output and no new timeline. 5. [Daily Signal, 2026-06-10] Admin moves to protect frozen embryos — potentially in tension with IVF practice, adding political complication. # Cross-market signals - **Kalshi related:** "Will Trump bring back manufacturing? Before 2029" at 14.5% — comparable low-probability ambitious promise market. "Will Trump cut $250B in spending?" at 14%. Pattern of ambitious Trump promise markets pricing ~14%. - **Polymarket:** No active IVF-related markets found. - **Sportsbook:** None found. # Analyst opinions and speculation - ASRM (2025-10): Administration initiative is "incremental" and falls well short of campaign promise. [ASRM] - KFF (2025): Drug discounts and voluntary employer pathways will not meaningfully expand IVF access for most Americans. [KFF] - Reproductive Freedom for All: Characterizes admin as "backtracking" on campaign promise. [reproductivefreedomforall.org] # Directional lean per outcome - **Yes (14%):** Supporting — Trump has political incentive, remaining ~2.5 years in term, IVF is popular (bipartisan), military IVF bills could pass. Opposing — Explicit WH rejection of mandate, no funding mechanism, Republican Congress not advancing bills, embryo-protection move complicates IVF politics, trend is downward. - **No (86%):** Strong evidence base — no mechanism exists, WH explicitly retreated from campaign promise, all actions voluntary/incremental, Congress inactive, ~2.5 years remain but political trajectory is away from resolution. # Gaps / unknowns - Whether proposed employer benefit rule will be finalized and whether courts might expand its scope. - Possibility of a surprise executive action (e.g., Medicaid/CHIP directive, military IVF mandate) not currently telegraphed. - Embryo-protection policy could further complicate IVF access and make "free IVF" politically harder. # Calibration anchors - **Kalshi anchor: 14% YES** — market has been stable in 12–17% range for 62 days, trending slightly down. - **Base rate analog:** Major healthcare policy promises rarely fulfilled unilaterally; ACA mandate repeal failed; drug pricing EOs had limited effect. - **Resolution bar is high:** Must *eliminate* cost of ≥1 cycle — discounts and voluntary caps do not qualify.

1. Both forecasters go below the Kalshi anchor (14%) without strong justification for diverging from it. The market has been stable in the 12–17% range for 62 days on low volume, suggesting limited new information is driving the price — yet both forecasters treat their downward deviation as well-supported when the evidence brief itself lists the anchor as a calibration reference they should account for more carefully. 2. Neither forecaster adequately explores the military IVF pathway, which the brief flags as a live scenario ("military IVF bills could pass") and the only bipartisan legislative track. A targeted military IVF mandate or executive action via DoD/VA channels would require no insurance mandate and has precedent (prior expansions of military health benefits), yet both treat "no funding mechanism" as near-conclusive. 3. Both forecasters underweight the ~2.5 years remaining in the term as a meaningful window. The brief notes the directional lean for "Yes" includes this, but neither forecaster engages with the base rate of how often a politically popular, frequently-promised policy gets enacted somewhere in a full four-year term when electoral incentives (2026 midterms) are still present. 4. The embryo-protection complication (June 2026 admin action) is noted in the brief as a political headwind, but neither forecaster examines whether this could actually increase pressure for a compensatory IVF-access gesture — a scenario where the administration tries to neutralize backlash by announcing a narrow "free IVF" program for a specific population. 5. Both forecasters treat "explicit WH rejection of an insurance mandate" as near-equivalent to "no path to free IVF," conflating the mandate mechanism with all possible mechanisms. A Medicaid waiver, direct federal subsidy program, or CHIP directive could theoretically eliminate cost for a subset of beneficiaries without mandating insurer coverage — the brief flags this gap but neither forecast engages with it.

12% (50% confidence)

Yes: 12% No: 88%

The resolution bar is high (fully eliminating cost of ≥1 cycle), and all current actions are incremental and voluntary, favoring No. However, the critique fairly notes forecasters diverged below the stable market anchor without strong justification, and alternate pathways (military IVF via DoD, Medicaid waivers, or a compensatory gesture amid embryo-protection backlash) remain plausible over ~2.5 years. I anchor to the Kalshi 14% but shade slightly down to 12% given the strict criterion and downward trend.

Total pipeline time: 157.6s